>
Date: Sat, 20 Apr 2002 18:21:03 -0700
BioE2E - Navigating the Biotech/University Deal
The details for our next event are now complete. see
http://www.bioe2e.org/2002/may1.html
Title: Navigating the Biotech/University Deal
Date: May 1, 2002 at 7:00pm
Location: Wilson Sonsini, 950 Page Mill Rd., Palo Alto, CA
Cost: $20, at the door.
San Francisco, San Antonio, San Diego, Seattle, Research Triangle,
Boston. The engines of economic growth in these regions have been all
driven by a critical mass of intellectual property coming out of
surrounding academic and other research institutions. The first step in
translating these ideas and inventions into commercial reality is the
university technology transfer office. When working with these
institutions, the entrepreneur should understand their goals and the
restrictions placed on technology transfer offices before entering
negotiations.
At this BioE2E event, experienced panelists from technology licensing
offices and entrepreneurs will discuss the process of technology
transfer from academia to the entrepreneur.
Topics will include:
(1) Overview of two perspectives of technology transfer
a. Academic perspective
b. Entrepreneurial perspective
(2) Sources of information on academic licensing
(3) The deal negotiation process
(4) Institution to institution variation
(5) Types of payment: royalties, cash, equity
(6) Licensing: exclusive, non-exclusive, options on new inventions
(7) Long term obligations to commercialize the technology
(8) Future of technology transfer - emergence and disappearance of
alternative channels
Featured Panelist Speakers
Kenneth A. Clark is Managing Partner of Wilson Sonsini Goodrich &
Rosati's Technology Transactions Group, which specializes in
transactions involving products and/or technology, from strategic
alliances to license, development, supply and distribution arrangements.
Ken has negotiated more than 40 major strategic alliance transactions in
both the information technology and life sciences industries. He also
regularly represents companies in spin-outs and core technology
licenses, as well as other technology transactions. From 1992 to 1993,
Ken served as Vice President, General Counsel & Secretary of Maxtor
Corporation, then a $1.5 billion disk drive manufacturer. He received
his undergraduate degree from Vanderbilt University and his law degree
from the University of Texas.
Joel Kirschbaum is Director and Senior Technology Portfolio Manager for
the UCSF Office of Technology Management. Joel has been with the office
since its inception in July, 1996. He has eleven years of experience as
a senior R&D manager in the biotechnology industry and twelve years of
experience as an independent R&D consultant and interim R&D manager for
clients comprising leading venture capitalists, entrepreneurs,
biotechnology firms, and pharmaceutical companies. Previously, he spent
fourteen years as an academic researcher in genetics, biochemistry, and
molecular biology including a faculty appointment at Harvard Medical
School. He received a Ph.D. in Biochemistry and Molecular Biology from
Harvard University (under James D. Watson) and earned a B.A. in
Chemistry from Pomona College (magna cum laude, Phi Beta Kappa).
Michael Kope is Director of Corporate Development for MedImmune, Inc.,
serving the MedImmune Vaccines unit formerly known as Aviron. He came
to Aviron a few years after having licensed the company its core
FluMistTM technology in 1995 from the University of Michigan, where he
served as the University's Intellectual Property Counsel and technology
transfer representative. With deep experience on both sides of the
fence, Mike has negotiated a broad range of business acquisition and
partnership agreements, designed strategies for technology protection
and promotion in many fields of research, written a variety of
university technology policies, served on faculty conflict of interest
committees, and facilitated a number of successful university spin-offs.
He received his JD from University of Michigan in 1990.
Barclay Kamb's practice focuses on the representation of biotechnology
and medical device companies, with particular expertise in transactions
involving intellectual property. Much of his practice is devoted to
negotiating and drafting corporate partnership agreements, licensing
arrangements, strategic alliances, joint venture agreements and other
sophisticated technology transactions. Mr. Kamb received a B.S. degree
in Biology from Stanford University in 1983. He conducted post-graduate
studies in biology at the Massachusetts Institute of Technology under a
National Science Foundation Fellowship award. He received a J.D. degree
in 1988 from the Boalt Hall School of Law, University of California at
Berkeley, where he was awarded the Prosser Prize in Contracts. Mr. Kamb
also served as an Associate Editor on the California Law Review.
The event will be at Wilson Sonsini Goodrich and Rosati conference hall,
950 Page Mill Road, Palo Alto across from Genencor and just west of 650
Page Mill (the main WSGR building). Directions are at the RSVP page.
It will help us for planning purposes if you RSVP. Please bring cash or
check. We will not be accepting advance payments or credit cards.
Receipts will be available. If you have any other questions, please
contact us at info_at_bioe2e.org
See you then,
The BioE2E Steering Committee
http://www.bioe2e.org
=================================================================
To unsubscribe from the sfbay mailing list send the
message body of "unsubscribe sfbay" to majordomo_at_swiss-list.com
or visit http://www.swiss-list.com/mailings/
Received on Sun Apr 21 2002 - 05:02:56 PDT
